DEPO-MEDROL WITH LIDOCAINE

This brand name is authorized in Canada, Hong Kong, Netherlands

Active ingredients

The drug DEPO-MEDROL WITH LIDOCAINE contains a combination of these active pharmaceutical ingredients (APIs):

1 Methylprednisolone UNII 43502P7F0P - METHYLPREDNISOLONE ACETATE

Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. Read about Methylprednisolone

2 Lidocaine UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. Read about Lidocaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H02BX01	Methylprednisolone, combinations	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS → H02BX Corticosteroids for systemic use, combinations
Discover more medicines within H02BX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 00260428
Country: HK	Department of Health Drug Office	Identifier(s): 00437
Country: NL	Z-Index G-Standaard	Identifier(s): 14040417
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 4847